Number of pages: 100 | Report Format: PDF | Published date: February 07, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
Report Attribute |
Details |
Market Size Value in 2021 |
US$ 34.51 billion |
Revenue Forecast in 2030 |
US$ 70.14 billion |
CAGR |
8.2% |
Base Year For Estimation |
2021 |
Forecast Period |
2022-2030 |
Historical Year |
2020 |
Segments Covered |
Application, Type, Type of Manufacturers, Synthesis Technology, Route of Administration, and Region |
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global peptide therapeutics market was valued at US$ 34.51 billion in 2021 and is expected to register a revenue CAGR of 8.2% to reach US$ 70.14 billion by 2030.
Peptide Therapeutics Market Fundamentals
Peptides are short chains of amino acids linked together by a peptide bond. They play a variety of roles within the cell, including signaling and anti-infective properties. The body naturally manufactures a variety of peptides, making them generally well-tolerated as therapies and having fewer adverse effects. This makes peptides of specific importance as therapeutic medications. The suitability of peptides for therapeutic usage is determined by the sequence, which can be based on peptides naturally produced by the body, peptides like those produced naturally, or a sequence novel to the body.
Peptide Therapeutics Market Dynamics
The rising incidences of chronic diseases, such as cancer, cardiovascular disease, and metabolic diseases, is the major factor driving revenue growth in the global peptide therapeutics market. Moreover, peptide drugs provide a broad range of therapeutic applications, and are low in toxicity, efficacy, safety, and tolerability. These factors are increasing the demand for peptide drugs. The growing investment in R&D activities related to peptide therapy and the presence of a strong pipeline are playing a significant role in the market expansion. Similarly, the growing technological advancements in peptide manufacturing fuels the revenue growth of the global market. The major companies are taking initiatives to develop novel peptide drug candidates for the conditions, such as diabetes, obesity, and infectious diseases. Additionally, the rising geriatric population with unhealthy lifestyle and the increasing demand for low-cost drugs is also expected to boost the revenue growth of the global market.
However, the rapid clearance due to the short half-life and low metabolic stability is resisting the revenue growth of the global market. Additionally, the high cost of the overall development of novel drugs is also cramping the revenue growth of the global market.
Peptide Therapeutics Market Ecosystem
The global peptide therapeutics market has been analyzed from six perspectives: application, type, type of manufacturers, synthesis technology, route of administration, and region.
Peptide Therapeutics Market by Application
Based on application, the global peptide therapeutics market is segmented into metabolic, cardiovascular disorder, respiratory, cancers, GTI, anti-infection, pain, renal, CNS, and others.
The metabolic disorders segment dominated the global peptide therapeutics market with the largest market revenue share in 2021. The large revenue share of the metabolic disorders segment can be attributed to the increasing prevalence of metabolic disorders, such as diabetes, obesity, and kidney disorders, with increased investment in developing novel peptide drugs for metabolic diseases. Similarly, the rising geriatric population that is more prone to metabolic disorders is also fueling the revenue growth of the segment. The rise in the adoption of unhealthy lifestyles and increased consumption of alcohol and tobacco products are boosting revenue growth in the segment.
Peptide Therapeutics Market by Type
Based on type, the global peptide therapeutics market is segmented into generic and innovative.
The innovation segment accounted for the largest revenue share of the global market in 2021. The rise in the investment in R&D activities by the major companies with a promising pipeline is the major factor driving the segment’s growth. Moreover, peptide drugs are two times more likely to get approval through clinical trials; thus, there is a rise in the research related to peptide drugs, which is boosting the segment’s revenue growth.
Peptide Therapeutics Market by Type of Manufacturers
Based on type of manufacturers, the global peptide therapeutics market is segmented into in-house and outsourced.
The in-house segment led the global market with the largest market share in 2021. The dominating revenue share of the in-house segment can largely be attributed to the rising cost of outscoring and issues related to patent copyrights. Moreover, the major players are involved in the development of peptide drugs as these companies have a well-developed infrastructure for the large-scale production of peptide drugs, thus boosting segment revenue growth.
Peptide Therapeutics Market by Synthesis Technology
Based on synthesis technology, the global peptide therapeutics market is segmented into solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid technology.
The liquid-phase peptide synthesis (LPPS) segment dominated the global market with the largest market revenue share in 2021. The liquid phase peptide synthesis is the basic approach of peptide synthesis, and it is used for large-scale production. However, the adoption of SPPS has increased over LPPS as it is faster, more efficient, and more economical. Moreover, SPPS is more compatible with automated synthesis technology.
Peptide Therapeutics Market by Route of Administration
Based on the route of administration, the global peptide therapeutics market is segmented into the parenteral route, oral route, pulmonary, and mucosal.
The parenteral route segment accounted for a significant revenue share of the global peptide therapeutics market in 2021. The parenteral route allows for advanced drug targeting and sustained release of medication, which is fueling revenue growth in the segment. Moreover, the half-life of peptide drugs is short; thus, targeted relies on the drugs are necessary, which results in increasing demand for the parenteral route of drug administration.
Peptide Therapeutics Market by Region
Based on region, the global peptide therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global peptide therapeutics market in 2021, followed by Europe and Asia Pacific. The rising awareness regarding peptide therapeutics and increased prevalence of chronic diseases are the major factors driving regional revenue growth. Moreover, presence of well-established biotech and pharma industries and increase in investments by government organizations for R&D activities related to peptide drugs boost regional revenue growth.
Peptide Therapeutics Market Competitive Landscape
The prominent players operating in the peptide therapeutics market are:
Peptide Therapeutics Market Strategic Developments
The global peptide therapeutics market is expected to be valued at US$ 70.14 billion by 2030.
Pfizer Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., and Novartis AG are among the key players operating in the global market.
The major market players are focusing on acquisition and drug development in collaboration with other market players.
The rising prevalence of chronic diseases and increasing demand for peptide drugs, as they provide a broad range of therapeutic applications, is the major driving factor of the market. Moreover, the rise in investment in R&D activities, together with the presence of a strong pipeline, are some of the driving factors of the global market.
The metabolic disorders segment accounts for the largest revenue share of the global peptide therapeutics market.
* Insights on financial performance are subject to the availability of information in the public domain